Adiponectin in inflammatory and immune-mediated diseases

Cytokine

Volumn 64, Issue 1, 2013, Pages 1-10

  Fantuzzi, Giamila ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adipokines; Adipose tissue; Disease; Immunity; Inflammation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIINFLAMMATORY AGENT; CADHERIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; SULFONYLUREA DERIVATIVE; T CADHERIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ADIPOCYTE; ADIPOSE TISSUE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; BODY MASS; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; COMMENSAL; CRITICAL ILLNESS; CYTOKINE PRODUCTION; FAT MASS; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEART FAILURE; HORMONAL REGULATION; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; INTESTINE FLORA; INTRAABDOMINAL FAT; IRON OVERLOAD; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE; LIVER DISEASE; LUNG DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS FAT;

MUS;

ADIPOKINES; ADIPONECTIN; ADIPOSE TISSUE; APN; BMI; BODY MASS INDEX; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COPD; CVD; DISEASE; GRAFT-VERSUS-HOST DISEASE; GVHD; IMMUNITY; INFLAMMATION; LIPOPOLYSACCHARIDE; LPS; MOLECULAR WEIGHT; MW; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PPAR; TLR; TOLL-LIKE RECEPTOR;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; DISEASE MODELS, ANIMAL; HEART DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; LUNG DISEASES; MICE; MICE, KNOCKOUT; OBESITY; ORGAN TRANSPLANTATION; RENAL INSUFFICIENCY;

EID: 84883551010     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.06.317     Document Type: Review

References (160)

1. Tishinsky J.M., Dyck D.J., Robinson L.E. Lifestyle factors increasing adiponectin synthesis and secretion. Vitam Horm 2012, 90:1-30.
2. Turer A.T., Scherer P.E. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012, 55:2319-2326.
3. Villarreal-Molina M.T., Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012, 94:2143-2149.
4. Summer R., Walsh K., Medoff B.D. Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions?. Pulm Circ 2011, 1:440-447.
5. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008, 121:326-330.
6. Garcia P., Sood A. Adiponectin in pulmonary disease and critically ill patients. Curr Med Chem 2012, 19:5493-5500.
7. Marques M.B., Langouche L. Endocrine, metabolic, and morphologic alterations of adipose tissue during critical illness. Crit Care Med 2013, 41:317-325.
8. Robinson K., Prins J., Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care 2011, 15:221.
9. Jia T., Carrero J.J., Lindholm B., Stenvinkel P. The complex role of adiponectin in chronic kidney disease. Biochimie 2012, 94:2150-2156.
10. Takeda Y., Nakanishi K., Tachibana I., Kumanogoh A. Adiponectin: a novel link between adipocytes and COPD. Vitam Horm 2012, 90:419-435.
11. Van Berendoncks A.M., Conraads V.M. Functional adiponectin resistance and exercise intolerance in heart failure. Curr Heart Fail Rep 2011, 8:113-122.
12. Kukla M., Mazur W., Buldak R.J., Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin - in chronic hepatitis. Mol Med 2011, 17:1397-1410.
13. Bobbert P., Scheibenbogen C., Jenke A., Kania G., Wilk S., Krohn S., et al. Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control. Eur Heart J 2011, 32:1134-1147.
14. Jortay J., Senou M., Abou-Samra M., Noel L., Robert A., Many M.C., et al. Adiponectin and skeletal muscle: pathophysiological implications in metabolic stress. Am J Pathol 2012, 181:245-256.
15. Miller M., Cho J.Y., Pham A., Ramsdell J., Broide D.H. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 2009, 182:684-691.
16. Crawford L.J., Peake R., Price S., Morris T.C., Irvine A.E. Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. J Leukoc Biol 2010, 88:807-811.
17. Hino K., Nagata H. Screening for adiponectin secretion regulators. Vitam Horm 2012, 90:125-141.
18. Ma K., Cabrero A., Saha P.K., Kojima H., Li L., Chang B.H., et al. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002, 277:34658-34661.
19. Tullin S., Sams A., Brandt J., Dahl K., Gong W., Jeppesen C.B., et al. Recombinant adiponectin does not lower plasma glucose in animal models of type 2 diabetes. PLoS ONE 2012, 7:e44270.
20. Holland W.L., Miller R.A., Wang Z.V., Sun K., Barth B.M., Bui H.H., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011, 17:55-63.
21. Toussirot E., Binda D., Gueugnon C., Dumoulin G. Adiponectin in autoimmune diseases. Curr Med Chem 2012, 19:5474-5480.
22. Adams V., Heiker J.T., Hollriegel R., Beck E.B., Woitek F.J., Erbs S., et al. Adiponectin promotes the migration of circulating angiogenic cells through p38-mediated induction of the CXCR4 receptor. Int J Cardiol 2012.
23. Addabbo F., Nacci C., De Benedictis L., Leo V., Tarquinio M., Quon M.J., et al. Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-kappaB/COX-2 signaling in human aortic endothelial cells. Am J Physiol Endocrinol Metab 2011, 301. E1143-54.
24. Ajuwon K.M., Spurlock M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005, 288. R1220-5.
25. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kubota N., Kaneko K., et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 2011, 13:401-412.
26. Devaraj S., Torok N., Dasu M.R., Samols D., Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008, 28:1368-1374.
27. Fang F., Liu G.C., Kim C., Yassa R., Zhou J., Scholey J.W. Adiponectin attenuates angiotensin II-induced oxidative stress in renal tubular cells through AMPK and cAMP-Epac signal transduction pathways. Am J Physiol Renal Physiol 2013.
28. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005, 97:1245-1252.
29. Park P.H., McMullen M.R., Huang H., Thakur V., Nagy L.E. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem 2007, 282:21695-21703.
30. Tang C.H., Chiu Y.C., Tan T.W., Yang R.S., Fu W.M. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol 2007, 179:5483-5492.
31. Tian L., Luo N., Zhu X., Chung B.H., Garvey W.T., Fu Y. Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis 2012, 221:66-75.
32. Tomizawa A., Hattori Y., Kasai K. Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci 2009, 85:457-461.
33. Tsao T.S., Murrey H.E., Hug C., Lee D.H., Lodish H.F. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30kDa (Acrp30). J Biol Chem 2002, 277:29359-29362.
34. Wanninger J., Neumeier M., Weigert J., Bauer S., Weiss T.S., Schaffler A., et al. Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol 2009, 297. G611-8.
35. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., Christian J.A., Spurlock M.E. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004, 316:924-929.
36. Yamaguchi N., Argueta J.G., Masuhiro Y., Kagishita M., Nonaka K., Saito T., et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005, 579:6821-6826.
37. Peake P.W., Shen Y., Campbell L.V., Charlesworth J.A. Human adiponectin binds to bacterial lipopolysaccharide. Biochem Biophys Res Commun 2006, 341:108-115.
38. Foucher A.L., Hartmann K., Hauptmann M., Wildgruber R., Safinowski M., Forst T., et al. Resolution of adiponectin oligomers in human plasma using free flow electrophoresis. Arch Physiol Biochem 2009, 115:267-278.
39. Cheng X., Folco E.J., Shimizu K., Libby P. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem 2012, 287:36896-36904.
40. Jung M.Y., Kim H.S., Hong H.J., Youn B.S., Kim T.S. Adiponectin induces dendritic cell activation via PLCgamma/JNK/NF-kappaB pathways, leading to Th1 and Th17 polarization. J Immunol 2012, 188:2592-2601.
41. Tsang J.Y., Li D., Ho D., Peng J., Xu A., Lamb J., et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol 2011, 11:604-609.
42. Pang T.T., Chimen M., Goble E., Dixon N., Benbow A., Eldershaw S.E., et al. Inhibition of islet immunoreactivity by adiponectin is attenuated in human type 1 diabetes. J Clin Endocrinol Metab 2013, 98. E418-28.
43. Wilk S., Scheibenbogen C., Bauer S., Jenke A., Rother M., Guerreiro M., et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol 2011, 41:2323-2332.
44. Palmer C., Hampartzoumian T., Lloyd A., Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008, 48:374-384.
45. Kim K.Y., Kim J.K., Han S.H., Lim J.S., Kim K.I., Cho D.H., et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol 2006, 176:5958-5964.
46. Wilk S., Jenke A., Stehr J., Yang C.A., Bauer S., Goldner K., et al. Adiponectin modulates NK-cell function. Eur J Immunol 2013.
47. Fayad R., Pini M., Sennello J.A., Cabay R.J., Chan L., Xu A., et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 2007, 132:601-614.
48. Gove M.E., Pini M., Fayad R., Cabay R.J., Fantuzzi G. Adiponectin deficiency modulates adhesion molecules expression and cytokine production but does not affect disease severity in the transfer model of colitis. Cytokine 2009, 47:119-125.
49. Nishihara T., Matsuda M., Araki H., Oshima K., Kihara S., Funahashi T., et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology 2006, 131:853-861.
50. Pini M., Gove M.E., Fayad R., Cabay R.J., Fantuzzi G. Adiponectin deficiency does not affect development and progression of spontaneous colitis in IL-10 knockout mice. Am J Physiol Gastrointest Liver Physiol 2009, 296. G382-7.
51. Nakanishi K., Takeda Y., Tetsumoto S., Iwasaki T., Tsujino K., Kuhara H., et al. Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: implications for therapy. Am J Respir Crit Care Med 2011, 183:1164-1175.
52. Summer R., Little F.F., Ouchi N., Takemura Y., Aprahamian T., Dwyer D., et al. Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol 2008, 294. L1035-42.
53. Kasahara D.I., Kim H.Y., Williams A.S., Verbout N.G., Tran J., Si H., et al. Pulmonary inflammation induced by subacute ozone is augmented in adiponectin-deficient mice: role of IL-17A. J Immunol 2012, 188:4558-4567.
54. Miller M., Pham A., Cho J.Y., Rosenthal P., Broide D.H. Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol 2010, 299. L834-42.
55. Okamoto Y., Christen T., Shimizu K., Asano K., Kihara S., Mitchell R.N., et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 2009, 88:879-883.
56. Li D., Tsang J.Y., Peng J., Ho D.H., Chan Y.K., Zhu J., et al. Adiponectin mediated MHC class II mismatched cardiac graft rejection in mice is IL-4 dependent. PLoS ONE 2012, 7:e48893.
57. Medoff B.D., Okamoto Y., Leyton P., Weng M., Sandall B.P., Raher M.J., et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 2009, 41:397-406.
58. Williams A.S., Kasahara D.I., Verbout N.G., Fedulov A.V., Zhu M., Si H., et al. Role of the adiponectin binding protein, T-cadherin (Cdh13), in allergic airways responses in mice. PLoS ONE 2012, 7:e41088.
59. Parker J., Menn-Josephy H., Laskow B., Takemura Y., Aprahamian T. Modulation of lupus phenotype by adiponectin deficiency in autoimmune mouse models. J Clin Immunol 2011, 31:167-173.
60. Yamada T., Araki H., Watabe K., Kamada Y., Kiso S., Ogiyama H., et al. Adiponectin deficiency enhanced the severity of cerulein-induced chronic pancreatitis in mice. J Gastroenterol 2010, 45:742-749.
61. Araki H., Nishihara T., Matsuda M., Fukuhara A., Kihara S., Funahashi T., et al. Adiponectin plays a protective role in caerulein-induced acute pancreatitis in mice fed a high-fat diet. Gut 2008, 57:1431-1440.
62. Konter J.M., Parker J.L., Baez E., Li S.Z., Ranscht B., Denzel M., et al. Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J Immunol 2012, 188:854-863.
63. Matsumoto H., Tamura S., Kamada Y., Kiso S., Fukushima J., Wada A., et al. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J Gastroenterol 2006, 12:3352-3358.
64. Pini M., Sennello J.A., Chan L., Fantuzzi G. Adiponectin deficiency does not affect the inflammatory response to endotoxin or concanavalin a in mice. Endocrinology 2006, 147:5019-5022.
65. Uji Y., Yamamoto H., Tsuchihashi H., Maeda K., Funahashi T., Shimomura I., et al. Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery 2009, 145:550-557.
66. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
67. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006, 281:2654-2660.
68. Takemura Y., Ouchi N., Shibata R., Aprahamian T., Kirber M.T., Summer R.S., et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007, 117:375-386.
69. Jin X., Chen J., Hu Z., Chan L., Wang Y. Genetic deficiency of adiponectin protects against acute kidney injury. Kidney Int 2013.
70. Rutkowski J.M., Wang Z.V., Park A.S., Zhang J., Zhang D., Hu M.C., et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013, 24:268-282.
71. Ebina K., Oshima K., Matsuda M., Fukuhara A., Maeda K., Kihara S., et al. Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. Biochem Biophys Res Commun 2009, 378:186-191.
72. Ishihara T., Haraguchi G., Konishi M., Ohigashi H., Saito K., Nakano Y., et al. Effect of adiponectin on cardiac allograft vasculopathy. Circ J 2011, 75:2005-2012.
73. Lee S.W., Kim J.H., Park M.C., Park Y.B., Lee S.K. Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. Scand J Rheumatol 2008, 37:260-268.
74. Shore S.A., Terry R.D., Flynt L., Xu A., Hug C. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol 2006, 118:389-395.
75. Masaki T., Chiba S., Tatsukawa H., Yasuda T., Noguchi H., Seike M., et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004, 40:177-184.
76. Al-Azzawi H.H., Ziegler K.M., Swartz-Basile D.A., Wang S., Pitt H.A., Zyromski N.J. Does adiponectin upregulation attenuate the severity of acute pancreatitis in obesity?. J Gastrointest Surg 2011, 15:1394-1400.
77. de Souza Barbosa V., Rego J., da Silva N.A. Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis. Rev Bras Reumatol 2012, 52:278-287.
78. Cantarini L., Brucato A., Simonini G., Imazio M., Cumetti D., Cimaz R., et al. Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report. Clin Exp Rheumatol 2013, 31:207-212.
79. Imagawa A., Funahashi T., Nakamura T., Moriwaki M., Tanaka S., Nishizawa H., et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002, 25:1665-1666.
80. Frystyk J., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005, 48:1911-1918.
81. Frommer K.W., Zimmermann B., Meier F.M., Schroder D., Heil M., Schaffler A., et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010, 62:2886-2899.
82. Conde J., Scotece M., Lopez V., Gomez R., Lago F., Pino J., et al. Adiponectin and leptin induce VCAM-1 expression in human and murine chondrocytes. PLoS ONE 2012, 7:e52533.
83. Pereira R.I., Snell-Bergeon J.K., Erickson C., Schauer I.E., Bergman B.C., Rewers M., et al. Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clin Endocrinol Metab 2012, 97. E642-7.
84. Tsiakou A., Liatis S., Alexiadou K., Diakoumopoulou E., Makrilakis K., Tentolouris N., et al. Arterial stiffness is inversely related to plasma adiponectin levels in young normotensive patients with type 1 diabetes. Diabetes Care 2013, 36:734-736.
85. Saraheimo M., Forsblom C., Thorn L., Waden J., Rosengard-Barlund M., Heikkila O., et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008, 31:1165-1169.
86. Forsblom C., Thomas M.C., Moran J., Saraheimo M., Thorn L., Waden J., et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 2011, 270:346-355.
87. Sysi-Aho M., Ermolov A., Gopalacharyulu P.V., Tripathi A., Seppanen-Laakso T., Maukonen J., et al. Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol 2011, 7:e1002257.
88. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Renal Nutr: Off J Counc Renal Nutr Natl Kidney Found 2011, 21:82-86.
89. Alam A., Molnar M.Z., Czira M.E., Rudas A., Ujszaszi A., Kalantar-Zadeh K., et al. Serum adiponectin levels and mortality after kidney transplantation. Clin J Am Soc Nephrol: CJASN. 2013, 8:460-467.
90. Halberg N., Schraw T.D., Wang Z.V., Kim J.Y., Yi J., Hamilton M.P., et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 2009, 58:1961-1970.
91. Martinez Cantarin M.P., Waldman S.A., Doria C., Frank A.M., Maley W.R., Ramirez C.B., et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 2013, 83:487-494.
92. Roubicek T., Bartlova M., Krajickova J., Haluzikova D., Mraz M., Lacinova Z., et al. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition 2009, 25:762-768.
93. Marchlewska A., Stenvinkel P., Lindholm B., Danielsson A., Pecoits-Filho R., Lonnqvist F., et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004, 66:46-50.
94. Cheng C.F., Lian W.S., Chen S.H., Lai P.F., Li H.F., Lan Y.F., et al. Protective effects of adiponectin against renal ischemia-reperfusion injury via prostacyclin-PPARalpha-heme oxygenase-1 signaling pathway. J Cell Physiol 2012, 227:239-249.
95. Chiang C.H., Lai J.S., Hung S.H., Lee L.T., Sheu J.C., Huang K.C. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring) 2012.
96. Hsu C.S., Liu C.H., Wang C.C., Tseng T.C., Liu C.J., Chen C.L., et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat 2012, 19. e48-57.
97. Tiftikci A., Atug O., Yilmaz Y., Eren F., Ozdemir F.T., Yapali S., et al. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009, 40:294-298.
98. Hung C.H., Lee C.M., Chen C.H., Hu T.H., Jiang S.R., Wang J.H., et al. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int 2009, 29:1086-1093.
99. Buechler C., Schaffler A., Johann M., Neumeier M., Kohl P., Weiss T., et al. Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol 2009, 24:558-563.
100. Chen M.J., Yeh Y.T., Lee K.T., Tsai C.J., Lee H.H., Wang S.N. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol 2012, 106:181-187.
101. Aksu H.S., Kurtaran B., Onlen Y., Namiduru M., Inkaya A.C., Kandemir O., et al. Association of insulin resistance, viral load, and adipokine levels with liver histology in patients with chronic hepatitis C: an observational, multicenter study in Turkey. Eur J Gastroenterol Hepatol 2012, 24:1393-1399.
102. Neumeier M., Hellerbrand C., Gabele E., Buettner R., Bollheimer C., Weigert J., et al. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006, 12:5490-5494.
103. Krommidas G., Kostikas K., Papatheodorou G., Koutsokera A., Gourgoulianis K.I., Roussos C., et al. Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. Respir Med 2010, 104:40-46.
104. Yuan Y., Jiang H., Kuang J., Hou X., Feng Y., Su Z. Genetic variations in ADIPOQ gene are associated with chronic obstructive pulmonary disease. PLoS ONE 2012, 7:e50848.
105. Keicho N., Matsushita I., Tanaka T., Shimbo T., Hang N.T., Sakurada S., et al. Circulating levels of adiponectin, leptin, fetuin-A and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation. PLoS ONE 2012, 7:e38703.
106. Kartalija M., Ovrutsky A.R., Bryan C.L., Pott G.B., Fantuzzi G., Thomas J., et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013, 187:197-205.
107. Sorice G.P., Di Pizio L., Sun V.A., Schiro T., Muscogiuri G., Mezza T., et al. Metabolic syndrome in transplant patients: an updating point of view. Minerva Endocrinol 2012, 37:211-220.
108. Nakasone H., Binh P.N., Yamazaki R., Tanaka Y., Sakamoto K., Ashizawa M., et al. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. Blood 2011, 117:3469-3472.
109. Roos M., Baumann M., Liu D., Heinemann F.M., Lindemann M., Horn P.A., et al. Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study. Regul Pept 2012, 178:11-15.
110. Lau W.B., Zhang Y., Zhao J., Liu B., Wang X., Yuan Y., et al. Lymphotoxin-alpha is a novel adiponectin expression suppressor following myocardial ischemia/reperfusion. Am J Physiol Endocrinol Metab 2013, 304. E661-7.
111. Tang H., Sebastian B.M., Axhemi A., Chen X., Hillian A.D., Jacobsen D.W., et al. Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res 2012, 36:214-222.
112. Wood I.S., Stezhka T., Trayhurn P. Modulation of adipokine production, glucose uptake and lactate release in human adipocytes by small changes in oxygen tension. Pflugers Arch 2011, 462:469-477.
113. Poggi M., Jager J., Paulmyer-Lacroix O., Peiretti F., Gremeaux T., Verdier M., et al. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009, 52:1152-1163.
114. Ho P.C., Wei L.N. Negative regulation of adiponectin secretion by receptor interacting protein 140 (RIP140). Cell Signal 2012, 24:71-76.
115. Kamon J., Yamauchi T., Muto S., Takekawa S., Ito Y., Hada Y., et al. A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem Biophys Res Commun 2004, 323:242-248.
116. van den Borst B., Gosker H.R., Wesseling G., de Jager W., Hellwig V.A., Snepvangers F.J., et al. Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease. Am J Clin Nutr 2011, 94:1504-1512.
117. Rossmeislova L., Malisova L., Kracmerova J., Tencerova M., Kovacova Z., Koc M., et al. Weight loss improves adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes 2013, 62:1990-1995.
118. Araujo J.P., Lourenco P., Rocha-Goncalves F., Ferreira A., Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009, 11:567-572.
119. Batista M.L., Olivan M., Alcantara P.S., Sandoval R., Peres S.B., Neves R.X., et al. Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine 2013, 61:532-539.
120. Langouche L., Perre S.V., Thiessen S., Gunst J., Hermans G., D'Hoore A., et al. Alterations in adipose tissue during critical illness: An adaptive and protective response?. Am J Respir Crit Care Med 2010, 182:507-516.
121. Langouche L., Marques M.B., Ingels C., Gunst J., Derde S., Vander Perre S., et al. Critical illness induces alternative activation of M2 macrophages in adipose tissue. Crit Care 2011, 15:R245.
122. Jurcovicova J., Stofkova A., Skurlova M., Baculikova M., Zorad S., Stancikova M. Alterations in adipocyte glucose transporter GLUT4 and circulating adiponectin and visfatin in rat adjuvant induced arthritis. Gen Physiol Biophys 2010, 29:79-84.
123. Kim J.Y., van de Wall E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007, 117:2621-2637.
124. Rhodes D.H., Pini M., Castellanos K.J., Montero-Melendez T., Cooper D., Perretti M., et al. Adipose tissue specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obesity (Silver Spring) 2013, 21:310-319.
125. Pang J., Rhodes D.H., Pini M., Akasheh R.T., Castellanos K.J., Cabay R.J., et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice. PLoS ONE 2013, 8:e57915.
126. Hajri T., Tao H., Wattacheril J., Marks-Shulman P., Abumrad N.N. Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-alpha and interleukin-6. Am J Physiol Endocrinol Metab 2011, 300. E350-60.
127. Li P., Zhang X.N., Pan C.M., Sun F., Zhu D.L., Song H.D., et al. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 2011, 43:464-469.
128. Chen B.Y., Tie R., Qu P., Zhu M.Z., Zhu X.X., Jin J., et al. Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes. J Endocrinol Invest 2011, 34:742-746.
129. Tsukamoto O., Fujita M., Kato M., Yamazaki S., Asano Y., Ogai A., et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009, 53:2070-2077.
130. Fasshauer M., Klein J., Neumann S., Eszlinger M., Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001, 507:142-146.
131. Ge Q., Maury E., Rycken L., Gerard J., Noel L., Detry R., et al. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity. Int J Obes (Lond) 2012, 16(5):5-9.
132. Huang Z.H., Manickam B., Ryvkin V., Zhou X.J., Fantuzzi G., Mazzone T., et al. PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity. J Clin Endocrinol Metab 2013, 98. E17-24.
133. Seki E., Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012, 590:447-458.
134. Pragman A.A., Kim H.B., Reilly C.S., Wendt C., Isaacson R.E. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 2012, 7:e47305.
135. Anders H.J., Andersen K., Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013, 83:1010-1016.
136. Hara N., Alkanani A.K., Ir D., Robertson C.E., Wagner B.D., Frank D.N., et al. The role of the intestinal microbiota in type 1 diabetes. Clin Immunol 2013, 146:112-119.
137. Yeoh N., Burton J.P., Suppiah P., Reid G., Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep 2013, 15:314.
138. Hayakawa M., Asahara T., Henzan N., Murakami H., Yamamoto H., Mukai N., et al. Dramatic changes of the gut flora immediately after severe and sudden insults. Dig Dis Sci 2011, 56:2361-2365.
139. Kim K.A., Gu W., Lee I.A., Joh E.H., Kim D.H. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE 2012, 7:e47713.
140. Carvalho F.A., Koren O., Goodrich J.K., Johansson M.E., Nalbantoglu I., Aitken J.D., et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 2012, 12:139-152.
141. Tsuchihashi H., Yamamoto H., Maeda K., Ugi S., Mori T., Shimizu T., et al. Circulating concentrations of adiponectin, an endogenous lipopolysaccharide neutralizing protein, decrease in rats with polymicrobial sepsis. J Surg Res 2006, 134:348-353.
142. Mandal P., Roychowdhury S., Park P.H., Pratt B.T., Roger T., Nagy L.E. Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. J Immunol 2010, 185:4928-4937.
143. Islam K.B., Fukiya S., Hagio M., Fujii N., Ishizuka S., Ooka T., et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011, 141:1773-1781.
144. Membrez M., Blancher F., Jaquet M., Bibiloni R., Cani P.D., Burcelin R.G., et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008, 22:2416-2426.
145. Luoto R., Laitinen K., Nermes M., Isolauri E. Impact of maternal probiotic-supplemented dietary counseling during pregnancy on colostrum adiponectin concentration: a prospective, randomized, placebo-controlled study. Early Hum Dev 2012, 88:339-344.
146. Ubeda C., Lipuma L., Gobourne A., Viale A., Leiner I., Equinda M., et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med 2012, 209:1445-1456.
147. Karki S., Chakrabarti P., Huang G., Wang H., Farmer S.R., Kandror K.V. The multi-level action of fatty acids on adiponectin production by fat cells. PLoS ONE 2011, 6:e28146.
148. Sukumar P., Sedo A., Li J., Wilson L.A., O'Regan D., Lippiat J.D., et al. Constitutively active TRPC channels of adipocytes confer a mechanism for sensing dietary fatty acids and regulating adiponectin. Circ Res 2012, 111:191-200.
149. Wang Z., Yao T., Pini M., Zhou Z., Fantuzzi G., Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2010, 298. G634-42.
150. Gabrielsen J.S., Gao Y., Simcox J.A., Huang J., Thorup D., Jones D., et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012, 122:3529-3540.
151. Tussing-Humphreys L., Pusatcioglu C., Nemeth E., Braunschweig C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. J Acad Nutr Diet 2012, 112:391-400.
152. Aso Y., Takebayashi K., Wakabayashi S., Momobayashi A., Sugawara N., Terasawa T., et al. Relation between serum high molecular weight adiponectin and serum ferritin or prohepcidin in patients with type 2 diabetes. Diabetes Res Clin Pract 2010, 90:250-255.
153. Lee F.P., Jen C.Y., Chang C.C., Chou Y., Lin H., Chou C.M., et al. Mechanisms of adiponectin-mediated COX-2 induction and protection against iron injury in mouse hepatocytes. J Cell Physiol 2010, 224:837-847.
154. Ozdemir M., Yuksel M., Gokbel H., Okudan N., Mevlitoglu I. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol 2012, 39:443-448.
155. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004, 101:10308-10313.
156. Denzel M.S., Scimia M.C., Zumstein P.M., Walsh K., Ruiz-Lozano P., Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010, 120:4342-4352.
157. Ling H., Waterworth D.M., Stirnadel H.A., Pollin T.I., Barter P.J., Kesaniemi Y.A., et al. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) 2009, 17:737-744.
158. Ellmann L., Joshi M.B., Resink T.J., Bosserhoff A.K., Kuphal S. BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells. Lab Invest 2012, 92:1788-1800.
159. Gumy-Pause F., Pardo B., Khoshbeen-Boudal M., Ansari M., Gayet-Ageron A., Sappino A.P., et al. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. Genes Chromosomes Cancer 2012, 51:174-185.
160. Ren J.Z., Huo J.R. Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells. Med Oncol 2012, 29:915-918.